NCT02928263View on ClinicalTrials.gov

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

February 28, 2017

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Renal Cell Carcinoma
Interventions
OTHER

Non-Interventional

Other

Trial Locations (1)

08540

Bristol-Myers Squibb, Princeton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02928263 - Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents | Biotech Hunter | Biotech Hunter